Neurent Medical
About
Neurent Medical is a Galway-based medtech company developing the NEUROMARK device, which uses proprietary Impedance Controlled Radiofrequency technology to target overactive posterior nasal nerves and treat chronic rhinitis — a condition affecting over 500 million people globally. Founded in 2015, the company closed an oversubscribed €62.5 million Series C in February 2026, led by MVM Partners with participation from Sofinnova Partners, EQT Life Sciences, Atlantic Bridge, and Enterprise Ireland, bringing total funding to over €100 million.
Investors 1
- Atlantic Bridge Venture Capital · Dublin
Recent news
- Neurent Medical Raises €62.5 million in Oversubscribed Series C Financing to Accelerate NEUROMARK Commercial Expansion 2026-02-11 · PR Newswire
- Neurent Medical Announces 510(k) Clearance of its Next Generation NEUROMARK System 2025-06-01 · PR Newswire